Explain the mechanism of acute respiratory distress syndrome

Reading Document

Medical Text Search

ARDS acute respiratory distress syndrome pathophysiology mechanism

Medical Text Search

ARDS diffuse alveolar damage phases exudative proliferative fibrotic

GradeResponse

Medical Text Search

ARDS exudative phase neutrophil cytokine alveolar epithelial injury pulmonary edema

Medical Image Search

ARDS pathophysiology diffuse alveolar damage mechanism diagram

GradeResponse

Acute Respiratory Distress Syndrome (ARDS): Mechanism

Definition and Core Pathophysiologic Features

ARDS is a syndrome defined by three cardinal pathophysiologic features (ARDS Definition Guidelines, p. 2):

Increased alveolo-capillary membrane permeability → inflammatory (non-cardiogenic) pulmonary edema
Increased non-aerated lung tissue → reduced lung compliance (higher elastance)
Increased venous admixture and dead space → hypoxemia (low PaO₂/FiO₂ ratio) and hypercapnia

Initiating Triggers

ARDS arises from either direct (pulmonary) or indirect (extrapulmonary) insults:

Direct	Indirect
Pneumonia (bacterial, viral, fungal)	Sepsis
Aspiration of gastric contents	Severe trauma / shock
Pulmonary contusion	Pancreatitis
Inhalation injury	Massive transfusion (TRALI)
Near-drowning	Burns

The Three Phases of ARDS

Harrison's Principles of Internal Medicine (p. 8196) describes a natural history of three overlapping phases, each with distinct cellular and structural features:

Phase 1 — Exudative Phase (Days 1–7)

This is the dominant inflammatory phase:

Initial insult activates alveolar macrophages, which release pro-inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-8.
These cytokines recruit neutrophils from the pulmonary capillaries into the alveolar space.
Activated neutrophils release:
- Reactive oxygen species (ROS)
- Proteases (elastase, matrix metalloproteinases)
- Myeloperoxidase (MPO)
- Neutrophil extracellular traps (NETs)
This toxic arsenal directly injures the alveolar epithelium (type I pneumocytes) and vascular endothelium.

Consequences of epithelial and endothelial injury:

Loss of tight junctions → protein-rich fluid floods the alveolar space (non-cardiogenic pulmonary edema)
Destruction of type II pneumocytes → impaired surfactant production → alveolar collapse (atelectasis)
Formation of hyaline membranes (fibrin + cellular debris lining the denuded alveoli) — the histologic hallmark of diffuse alveolar damage (DAD)
Platelet-neutrophil complexes (via P-selectin/PSGL-1 interactions) amplify microvascular injury

Physiologic result: Flooded, collapsed alveoli create intrapulmonary shunt → refractory hypoxemia. The non-aerated but perfused lung units are unresponsive to supplemental oxygen alone.

ARDS cellular and molecular mechanisms diagram

ARDS pathophysiology: viral/inflammatory activation of macrophages and neutrophils leading to diffuse alveolar damage and hyaline membrane formation

Phase 2 — Proliferative Phase (Days 7–21)

If the patient survives:

Type II pneumocytes proliferate to resurface the denuded alveolar epithelium and differentiate into type I cells.
Inflammation begins to resolve; macrophage phenotype shifts toward anti-inflammatory (M2).
Fibroblast migration and proliferation begins — early fibroproliferation.
Edema fluid is reabsorbed as the epithelial barrier is restored.

Most patients improve during this phase, though lung mechanics remain abnormal.

Phase 3 — Fibrotic Phase (Weeks to Months)

A subset of patients progress to:

Extensive fibrosis of the alveolar walls, interstitium, and airspaces
Architectural distortion of lung parenchyma
Obliteration of the pulmonary microvasculature → pulmonary hypertension
Cystic changes and a "honeycomb" pattern on imaging
Persistent dead space ventilation → hypercapnia and ventilator dependence

The stimulus for fibrosis appears to be sustained TGF-β signaling and disordered repair. This phase carries the highest mortality and longest ICU course.

Key Molecular Mediators Summary

Mediator	Source	Effect
TNF-α, IL-1β, IL-6	Macrophages	Neutrophil recruitment, systemic inflammation
IL-8 (CXCL8)	Epithelium, macrophages	Potent neutrophil chemoattractant
ROS, MPO	Neutrophils	Direct oxidative tissue injury
NETs	Neutrophils	Endothelial/epithelial damage, thrombosis
TGF-β	Multiple	Fibroproliferation, impaired epithelial repair
Surfactant deficit	Injured type II cells	Alveolar collapse, reduced compliance

Physiologic Consequences

Reduced PaO₂/FiO₂ ratio (Berlin criteria: <300 mmHg with PEEP ≥5 cmH₂O)
Reduced lung compliance — "stiff lungs" requiring high airway pressures
Intrapulmonary shunting — perfusion of non-ventilated alveoli
Increased dead space — ventilation of non-perfused units → CO₂ retention
Pulmonary hypertension — hypoxic vasoconstriction + vascular remodeling → right ventricular strain

Summary

ARDS is fundamentally a syndrome of uncontrolled innate immune activation causing diffuse alveolar damage. The inciting insult — whether pulmonary or systemic — activates macrophages and recruits neutrophils, whose cytotoxic arsenal destroys the alveolo-capillary barrier. The result is flooding of alveoli with protein-rich edema, loss of surfactant, and refractory hypoxemia. Recovery depends on the balance between further injury and epithelial repair; fibroproliferation in a subset leads to irreversible lung remodeling.

This is a shared conversation. Sign in to Orris to start your own chat.